ROVI 9M 2026 Net Profit Jumps 67% Year-on-Year to EUR 162.8 Million

By Public Technologies
  • ROVI’s net profit rose 67% year over year to EUR 162.8 million in the first nine months of 2026.
  • Revenue climbed 16% year over year to EUR 610.2 million.
  • Results included a EUR 62.4 million nonrecurring bargain-purchase gain from the acquisition of the Phoenix manufacturing plant.
  • ROVI raised its 2026 revenue growth outlook to mid-to-high single digits, citing stronger expected contract manufacturing growth and higher bemiparin partner volumes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Farmacéuticos ROVI SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.